Kalaris Therapeutics, Inc. KLRS
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) is an ophthalmology drug developer. Its lead program, TH103, is in Phase 1 for Neovascular age-related macular degeneration (nAMD). Its next catalyst on record is TH103: Preliminary data from Phase 1b/2 trial (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TH103 — Preliminary data from Phase 1b/2 trial (H1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TH103 | nAMD (Phase 1b/2 multiple-ascending-dose dose-finding study, up to 80 pts, ongoing; Phase 1a SAD complete with 20 pts) | protein/peptide | Phase 1 |
| TH103 | Diabetic macular edema, diabetic retinopathy, retinal vein occlusion (planned expansion) | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.